Literature DB >> 33897066

Adverse Effects of Recreational and Medical Cannabis.

Ivan Urits1, Karina Charipova1, Kyle Gress1, Nathan Li1, Amnon A Berger1, Elyse M Cornett1, Hisham Kassem1, Anh L Ngo1, Alan D Kaye1, Omar Viswanath1.   

Abstract

Purpose of Review: This comprehensive review discusses the adverse effects known today about marijuana, for either medical or recreational use. It reviews the role of cannabis in the treatment of chronic pain, cognitive and neurological adverse effects, special cases and addiction. Recent Findings: Cannabinoids work through the endocannabinoids system and inhibit the release of GABA and glutamate in the brain, impact neuromodulation, as well as dopamine, acetylcholine and norepinephrine release. They affect reward, learning and pain. The use of cannabis is increasing nationally and world-wide for both recreational and medicinal purposes, however, there is relatively only low quality evidence to the efficacy and adverse effects of this. Cannabis and its derivatives may be used for treatment of chronic pain. They are via CB1 receptors that are thought to modulate nociceptive signals in the brain. CB2 receptors in the DRG likely affect pain integration in the afferent pathways, and peripherally CB2 also affects noradrenergic pathways influencing pain. A large proportion of users may see more than 50% of chronic pain alleviation compared with placebo. Cannabis affects cognition, most notably executive function, memory and attention, and may deteriorate the boundary between emotional and executive processing. Cannabis impairs memory in the short run, which become more significant with chronic use, and may also be accompanied by poorer effort, slower processing and impacted attention. It is generally believed that long-term use and earlier age are risk factor for neurocognitive deficits; neuroimaging studies have shown reduced hippocampal volume and density. Executive functions and memory are worse in adolescent users versus adults. Cannabis addiction is different and likely less common than other addictive substances, but up to 10% of users meet criteria for lifetime cannabis dependence. Addiction patterns may be linked to genetic and epigenetic differences. It is still unclear whether abstinence reverses patterns of addiction, and more research is required into this topic. Summary: Cannabis use has become more abundant for both medical and recreational use. It carries likely benefits in the form of analgesia, anti-emesis and improved appetite in chronic patients. The evidence reviewing adverse effects of this use are still limited, however, exiting data points to a clear link with neurocognitive deterioration, backed by loss of brain volume and density. Addiction is likely complex and variable, and no good data exists to support treatment at this point. It is becoming clear that use in earlier ages carries a higher risk for long-term deficits. As with any other drug, these risks should be considered alongside benefits prior to a decision on cannabis use.
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  addiction; cannabis use disorder; hippocampal volume; marijuana

Mesh:

Substances:

Year:  2021        PMID: 33897066      PMCID: PMC8063125     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  41 in total

Review 1.  Cannabis and mental illness: a review.

Authors:  Darby J E Lowe; Julia D Sasiadek; Alexandria S Coles; Tony P George
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-12-19       Impact factor: 5.270

2.  Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study.

Authors:  Madeline H Meier; Avshalom Caspi; Andrea Danese; Helen L Fisher; Renate Houts; Louise Arseneault; Terrie E Moffitt
Journal:  Addiction       Date:  2017-09-05       Impact factor: 6.526

Review 3.  Adverse Structural and Functional Effects of Marijuana on the Brain: Evidence Reviewed.

Authors:  David E Mandelbaum; Suzanne M de la Monte
Journal:  Pediatr Neurol       Date:  2016-09-13       Impact factor: 3.372

Review 4.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

5.  Time since first cannabis use and 12-month prevalence of cannabis use disorder among youth and emerging adults in the United States.

Authors:  Beth Han; Wilson M Compton; Carlos Blanco; Christopher M Jones
Journal:  Addiction       Date:  2018-12-21       Impact factor: 6.526

6.  Cannabis smoke can be a major risk factor for early-age laryngeal cancer--a molecular signaling-based approach.

Authors:  Sayantan Bhattacharyya; Syamsundar Mandal; Samir Banerjee; Gautam Kumar Mandal; Anup Kumar Bhowmick; Nabendu Murmu
Journal:  Tumour Biol       Date:  2015-03-04

7.  Trying to remember: Effort mediates the relationship between frequency of cannabis use and memory performance.

Authors:  Rayna B Hirst; Kaitlyn R Young; Louise M Sodos; Robert E Wickham; Mitch Earleywine
Journal:  J Clin Exp Neuropsychol       Date:  2016-10-18       Impact factor: 2.475

8.  Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition.

Authors:  Larissa J Mooney; Yuhui Zhu; Caroline Yoo; Jonathan Valdez; Kevin Moino; Jung-Yu Liao; Yih-Ing Hser
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-03       Impact factor: 4.147

9.  Cannabis use and risk of schizophrenia: a Mendelian randomization study.

Authors:  J Vaucher; B J Keating; A M Lasserre; W Gan; D M Lyall; J Ward; D J Smith; J P Pell; N Sattar; G Paré; M V Holmes
Journal:  Mol Psychiatry       Date:  2017-01-24       Impact factor: 15.992

10.  Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage.

Authors:  Taylor Newman; Laya P Krishnan; Jessica Lee; Guy R Adami
Journal:  Sci Rep       Date:  2019-09-03       Impact factor: 4.379

View more
  2 in total

1.  Comparative Study of Δ9-Tetrahydrocannabinol and Cannabidiol on Melanogenesis in Human Epidermal Melanocytes from Different Pigmentation Phototypes: A Pilot Study.

Authors:  Shilpi Goenka
Journal:  J Xenobiot       Date:  2022-06-10

2.  Medical Students' Attitudes, Knowledge, and Beliefs about Medical Cannabis: A Qualitative Descriptive Study.

Authors:  Robin J Jacobs; Jessica Colon; Michael N Kane
Journal:  Cureus       Date:  2022-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.